• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial
Publication date: June 2019Source: The Lancet Neurology, Volume 18, Issue 6Author(s): Kazunori Toyoda, Shinichiro Uchiyama, Takenori Yamaguchi, J Donald Easton, Kazumi Kimura, Haruhiko Hoshino, Nobuyuki Sakai, Yasushi Okada, Kortaro Tanaka, Hideki Origasa, Hiroaki Naritomi, Kiyohiro Houkin, Keiji Yamaguchi, Masanori Isobe, Kazuo Minematsu, Shinya Goto, Tatsuya Isomura, Masayasu Matsumoto, Yasuo Terayama, Hidekazu TomimotoSummaryBackgroundAlthough dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of...
Source: The Lancet Neurology - May 22, 2019 Category: Neurology Source Type: research

Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I)
Publication date: March 2019Source: The Lancet Neurology, Volume 18, Issue 3Author(s): Akira Ogawa, Kazunori Toyoda, Kazuo Kitagawa, Takanari Kitazono, Takehiko Nagao, Hiroshi Yamagami, Shinichiro Uchiyama, Norio Tanahashi, Masayasu Matsumoto, Kazuo Minematsu, Izumi Nagata, Masakatsu Nishikawa, Shinsuke Nanto, Kenji Abe, Yasuo Ikeda, PRASTRO-I Study GroupSummaryBackgroundThe effect of prasugrel in terms of the prevention of recurrence of ischaemic stroke is unknown. We investigated the non-inferiority of prasugrel to clopidogrel for prevention of ischaemic stroke, myocardial infarction, and death from other vascular causes...
Source: The Lancet Neurology - February 14, 2019 Category: Neurology Source Type: research